Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth

NEW YORK, May 21, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Celgene Corporation (NASDAQ: CELG), Novartis AG (NYSE: NVS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2747-100free.

--
Johnson & Johnson Analyst Notes
On May 16, 2014, Janssen-Cilag International NV (Janssen-Cilag), a part of the Johnson & Johnson, announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has received marketing authorization from the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products. According to the Company, this marketing authorization is a key milestone in the development of new triple therapy hepatitis C (HCV) treatment options for genotype 1 and 4 patients. Thomas Stark, Medical Director, Janssen EMEA, said, "The EC marketing authorisation for simeprevir is a great milestone as it adds an important new treatment option for patients, demonstrating the continued role of triple therapy in the treatment of HCV." The full analyst notes on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/2747-JNJ-21May2014.pdf

--
Merck & Co. Inc. Analyst Notes
On May 14, 2014, Merck & Co. Inc. (Merck) announced that new data for the Company's investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer, are scheduled to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on May 30, 2014 - June 3, 2014. The Company informed that the first presentation of data for MK-3475 as initial treatment in advanced NSCLC and for the treatment of advanced head and neck cancer will be part of oral sessions at ASCO 2014. Commenting on the development, Dr. Roger M. Perlmutter, President, Merck Research Laboratories, said "The data to be presented expands our understanding of the effects of monotherapy with MK-3475, and will serve as a foundation for future studies of combination therapies in an even broader set of malignancies." The full analyst notes on Merck are available to download free of charge at:

http://www.analystsreview.com/2747-MRK-21May2014.pdf

--
Celgene Corporation Analyst Notes
On May 14, 2014, Celgene International Sàrl, (Celgene Sàrl) a wholly-owned subsidiary of Celgene Corporation (Celgene), announced that more than 65 abstracts reporting on investigational studies in blood and solid tumor cancers will be presented during the 50th American Society of Clinical Oncology meeting in Chicago, Illinois, from May 30, 2014 to June 3, 2014. Celgene informed that a complete listing of abstracts is available on ASCO website. The full analyst notes on Celgene are available to download free of charge at:

http://www.analystsreview.com/2747-CELG-21May2014.pdf

--
Novartis AG Analyst Notes
On May 16, 2014, Novartis AG (Novartis) announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), in relation to its Biologics License Application (BLA) for RLX030 (serelaxin) for the treatment of acute heart failure (AHF). According to the Company, the letter from FDA states that further evidence on the efficacy of RLX030 is required for a U.S. license to be granted. The RLX030 submission to the FDA included phase II and III efficacy and safety data from the clinical development program, including the pivotal phase III RELAX-AHF study. Tim Wright, Global Head of Development, Novartis Pharmaceuticals, said, "In accordance with the FDA's advice we will continue to expedite our clinical trial program to build the supporting body of evidence." The full analyst notes on Novartis are available to download free of charge at:

http://www.analystsreview.com/2747-NVS-21May2014.pdf

--
UnitedHealth Group Inc. Analyst Notes
On May 15, 2014, UnitedHealthcare Community Plan, a UnitedHealth Group Company, announced that it is offering two text-messaging services -- Txt4health and Text4kids -- that help people enrolled in Medicaid benefit plans take charge of their health and well-being. According to the Company, Txt4health service provides personalized messages to people that help them in following preventive care guidelines, timely intake of medications, medical appointments, track weight, exercise goals, learn healthy eating and nutrition tips. The Text4kids services helps parents remember well-child visits, learn more about vaccine safety, and track their child's growth. Both the Txt4health and Text4kids are available now at no charge to people enrolled in UnitedHealthcare Medicaid plans in York, Allegheny and Philadelphia Counties. Susan Schick, CEO of UnitedHealthcare of Pennsylvania, said, "Txt4health and Text4kids provide useful health information for people in a convenient, cost-effective way, no matter where they are." The full analyst notes on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/2747-UNH-21May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review